| Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study H Barthel, HJ Gertz, S Dresel, O Peters, P Bartenstein, K Buerger, ... The Lancet Neurology 10 (5), 424-435, 2011 | 614 | 2011 |
| Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma M Dreyling, A Santoro, L Mollica, S Leppä, GA Follows, G Lenz, WS Kim, ... Journal of Clinical Oncology 35 (35), 3898-3905, 2017 | 375 | 2017 |
| Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study JF Korobelnik, FG Holz, J Roider, Y Ogura, C Simader, U Schmidt-Erfurth, ... Ophthalmology 121 (1), 202-208, 2014 | 331 | 2014 |
| VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study FG Holz, J Roider, Y Ogura, JF Korobelnik, C Simader, G Groetzbach, ... British Journal of Ophthalmology, 2013 | 286 | 2013 |
| Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma M Dreyling, F Morschhauser, K Bouabdallah, D Bron, D Cunningham, ... Annals of Oncology, 2017 | 253 | 2017 |
| Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study Y Ogura, J Roider, JF Korobelnik, FG Holz, C Simader, U Schmidt-Erfurth, ... American journal of ophthalmology 158 (5), 1032-1038. e2, 2014 | 190 | 2014 |
| Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study M Dreyling, A Santoro, L Mollica, S Leppä, G Follows, G Lenz, WS Kim, ... American journal of hematology 95 (4), 362-371, 2020 | 124 | 2020 |
| A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of … HM Behre, TLJ Tammela, S Arver, JR Tolrá, V Bonifacio, M Lamche, ... The Aging Male 15 (4), 198-207, 2012 | 119 | 2012 |
| Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled … MJ Matasar, M Capra, M Özcan, F Lv, W Li, E Yañez, K Sapunarova, T Lin, ... The Lancet Oncology 22 (5), 678-689, 2021 | 104 | 2021 |
| Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma G Lenz, E Hawkes, G Verhoef, C Haioun, S Thye Lim, D Seog Heo, ... Leukemia 34 (8), 2184-2197, 2020 | 56 | 2020 |
| Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma P Panayiotidis, GA Follows, L Mollica, A Nagler, M Özcan, A Santoro, ... Blood Advances 5 (3), 823-828, 2021 | 22 | 2021 |
| Copanlisib in patients with relapsed or refractory indolent B‐cell lymphoma (CHRONOS‐1) M Dreyling, A Santoro, L Mollica, S Leppä, GA Follows, G Lenz, W Kim, ... Hematological Oncology 35, 119-120, 2017 | 18* | 2017 |
| Micro-dose transdermal estradiol for relief of hot flushes in postmenopausal Asian women: a randomized controlled trial C Haines, SL Yu, F Hiemeyer, M Schaefers Climacteric 12 (5), 419-426, 2009 | 15 | 2009 |
| Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). G Lenz, E Hawkes, G Verhoef, C Haioun, LS Thye, DS Heo, K Ardeshna, ... Journal of Clinical Oncology 35 (15_suppl), 7536-7536, 2017 | 13 | 2017 |
| Long-term efficacy and safety from the copanlisib CHRONOS-1 study in patients with relapsed or refractory indolent B-cell lymphoma M Dreyling, A Santoro, L Mollica, S Leppä, GA Follows, G Lenz, WS Kim, ... Blood 132, 1595, 2018 | 12 | 2018 |
| Results of the mantle cell lymphoma subset from a phase 2a study of copanlisib, a novel PI3K inhibitor, in patients with indolent and aggressive lymphoma D Cunningham, PL Zinzani, SE Assouline, K Bouabdallah, D Bron, ... Blood 126 (23), 3935, 2015 | 10 | 2015 |
| An empirically validated responder definition for the reduction of moderate to severe hot flushes in postmenopausal women C Gerlinger, K Gude, F Hiemeyer, T Schmelter, M Schäfers Menopause 19 (7), 799-803, 2012 | 10 | 2012 |
| CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM a PHASE II STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA G Lenz, E Hawkes, G Verhoef, C Haioun, S Lim, D Heo, K Ardeshna, ... Hematological Oncology 35, 68-69, 2017 | 9 | 2017 |
| EFFICACY AND SAFETY IN HIGH‐RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB M Dreyling, A Santoro, S Leppä, J Demeter, GA Follows, G Lenz, WS Kim, ... Hematological Oncology 37, 387-389, 2019 | 7 | 2019 |
| Intravitrial aflibercept injection for macular edema in central retinal vein occlusion: 1-year results of the phase 3 GALILEO study FG Holz, Y Ogura, J Roider, JF Korobelnik, B Stemper, R Vitti, AJ Berliner, ... Investigative Ophthalmology & Visual Science 53 (14), 6929-6929, 2012 | 7 | 2012 |
Pier Luigi ZinzaniUniversità di BolognaAdresse e-mail validée de unibo.it
